MedTrace Logo

Effects of Single Oral Dose Dapagliflozin QT Study

NCT00688493 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-03-21

No results posted yet for this study

Summary

The main purpose of this study is to examine the effect of dapagliflozin on electronic measures of heart beats in healthy males

Conditions

  • Healthy

Interventions

DRUG

Dapagliflozin

3 x 50 mg tablets, single oral dose

DRUG

Dapagliflozin

2 x 10 mg capsules, single oral dose

DRUG

Moxifloxacin

Overencapsulated 400 mg capsule, single oral dose

DRUG

Placebo to match moxifloxacin and dapagliflozin

Overencapsulated 400 mg capsule, single oral dose

Sponsors & Collaborators

Principal Investigators

  • Glenn Carlson, MD · AstraZeneca

  • Ronald Goldwater, MD · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00688493 on ClinicalTrials.gov